Baidu
map

感染

订阅

MedSci主页 / 所有栏目 / 感染

J Virol：我国建立HCV感染性DNA克隆

2014-01-02 黄辛 中国科学报

丙型肝炎病毒HCV感染性DNA克隆
关注

记者日前从中科院上海巴斯德所获悉，该所钟劲课题组和上海交通大学附属瑞金医院谢青课题组合作，建立了我国首例丙型肝炎病毒（HCV）感染性DNA克隆，为下一步抗HCV药物和疫苗的研发带来极大便利。相关成果在线发表于《病毒学杂志》。【原文下载】 HCV细胞感染模型对于HCV生物学研究、抗病毒药物和疫苗研发具有重要作用，其中HCV感染性cDNA克隆的建立很关键。由于HCV基因组的变异很大，不同基因

记者日前从中科院上海巴斯德所获悉，该所钟劲课题组和上海交通大学附属瑞金医院谢青课题组合作，建立了我国首例丙型肝炎病毒（HCV）感染性DNA克隆，为下一步抗HCV药物和疫苗的研发带来极大便利。相关成果在线发表于《病毒学杂志》。【原文下载】

HCV细胞感染模型对于HCV生物学研究、抗病毒药物和疫苗研发具有重要作用，其中HCV感染性cDNA克隆的建立很关键。由于HCV基因组的变异很大，不同基因型HCV对治疗方案的敏感性有所不同，因此有必要建立更多来源于不同感染性克隆的细胞感染模型。

研究人员利用一例基因型2aHCV临床分离株（PR63）样本，通过功能性克隆筛选、拼接及引入细胞适应性突变，构建了它的全长感染性cDNA克隆（PR63cc），进而建立了基于PR63cc的HCV细胞感染模型。

据悉，PR63cc是第一例来源于中国丙肝患者样本的全长感染性克隆，也是世界上首例不通过共有序列，直接从临床样本来源构建的能感染肝细胞系的感染性克隆。

原文出处：

Lu J, Xiang Y, Tao W, Li Q, Wang N, Gao Y, Xiang X, Xie Q, Zhong J.A novel strategy to develop robust infectious hepatitis C virus cell culture system directly from a clinical isolate.J Virol. 2013 Nov 13. 【原文下载】

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2077336, encodeId=b87820e7336eb, content=<a href='/topic/show?id=cb141845040' target=_blank style='color:#2F92EE;'>#Virol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18450, encryptionId=cb141845040, topicName=Virol)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/FGFAawy0kQNXbuvUuLtUVrx5aKhOIkwqJwyxu0QlpLFIDSb1Ht19ptXvYBjuAoNBubibnNF3iazdpico7gJlbBVQg/132, createdBy=edaf2500125, createdName=ms3892185887221420, createdTime=Tue Mar 04 22:48:00 CST 2014, time=2014-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660092, encodeId=5f841660092ce, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Wed Mar 19 00:48:00 CST 2014, time=2014-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655322, encodeId=34cf165532261, content=<a href='/topic/show?id=7c2853311ac' target=_blank style='color:#2F92EE;'>#感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53311, encryptionId=7c2853311ac, topicName=感染性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=583d24724321, createdName=charl1234575, createdTime=Sun Jul 13 11:48:00 CST 2014, time=2014-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257581, encodeId=a2dc125e58192, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Sat Jan 04 05:48:00 CST 2014, time=2014-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618952, encodeId=bd17161895251, content=<a href='/topic/show?id=5f1785e9d5' target=_blank style='color:#2F92EE;'>#HCV感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8579, encryptionId=5f1785e9d5, topicName=HCV感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cb419968800, createdName=12498e5fm18(暂无昵称), createdTime=Sat Jan 04 05:48:00 CST 2014, time=2014-01-04, status=1, ipAttribution=)]
    2014-03-04 ms3892185887221420

    #Virol#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2077336, encodeId=b87820e7336eb, content=<a href='/topic/show?id=cb141845040' target=_blank style='color:#2F92EE;'>#Virol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18450, encryptionId=cb141845040, topicName=Virol)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/FGFAawy0kQNXbuvUuLtUVrx5aKhOIkwqJwyxu0QlpLFIDSb1Ht19ptXvYBjuAoNBubibnNF3iazdpico7gJlbBVQg/132, createdBy=edaf2500125, createdName=ms3892185887221420, createdTime=Tue Mar 04 22:48:00 CST 2014, time=2014-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660092, encodeId=5f841660092ce, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Wed Mar 19 00:48:00 CST 2014, time=2014-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655322, encodeId=34cf165532261, content=<a href='/topic/show?id=7c2853311ac' target=_blank style='color:#2F92EE;'>#感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53311, encryptionId=7c2853311ac, topicName=感染性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=583d24724321, createdName=charl1234575, createdTime=Sun Jul 13 11:48:00 CST 2014, time=2014-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257581, encodeId=a2dc125e58192, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Sat Jan 04 05:48:00 CST 2014, time=2014-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618952, encodeId=bd17161895251, content=<a href='/topic/show?id=5f1785e9d5' target=_blank style='color:#2F92EE;'>#HCV感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8579, encryptionId=5f1785e9d5, topicName=HCV感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cb419968800, createdName=12498e5fm18(暂无昵称), createdTime=Sat Jan 04 05:48:00 CST 2014, time=2014-01-04, status=1, ipAttribution=)]
    2014-03-19 aids221

    #克隆#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2077336, encodeId=b87820e7336eb, content=<a href='/topic/show?id=cb141845040' target=_blank style='color:#2F92EE;'>#Virol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18450, encryptionId=cb141845040, topicName=Virol)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/FGFAawy0kQNXbuvUuLtUVrx5aKhOIkwqJwyxu0QlpLFIDSb1Ht19ptXvYBjuAoNBubibnNF3iazdpico7gJlbBVQg/132, createdBy=edaf2500125, createdName=ms3892185887221420, createdTime=Tue Mar 04 22:48:00 CST 2014, time=2014-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660092, encodeId=5f841660092ce, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Wed Mar 19 00:48:00 CST 2014, time=2014-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655322, encodeId=34cf165532261, content=<a href='/topic/show?id=7c2853311ac' target=_blank style='color:#2F92EE;'>#感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53311, encryptionId=7c2853311ac, topicName=感染性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=583d24724321, createdName=charl1234575, createdTime=Sun Jul 13 11:48:00 CST 2014, time=2014-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257581, encodeId=a2dc125e58192, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Sat Jan 04 05:48:00 CST 2014, time=2014-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618952, encodeId=bd17161895251, content=<a href='/topic/show?id=5f1785e9d5' target=_blank style='color:#2F92EE;'>#HCV感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8579, encryptionId=5f1785e9d5, topicName=HCV感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cb419968800, createdName=12498e5fm18(暂无昵称), createdTime=Sat Jan 04 05:48:00 CST 2014, time=2014-01-04, status=1, ipAttribution=)]
    2014-07-13 charl1234575

    #感染性#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2077336, encodeId=b87820e7336eb, content=<a href='/topic/show?id=cb141845040' target=_blank style='color:#2F92EE;'>#Virol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18450, encryptionId=cb141845040, topicName=Virol)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/FGFAawy0kQNXbuvUuLtUVrx5aKhOIkwqJwyxu0QlpLFIDSb1Ht19ptXvYBjuAoNBubibnNF3iazdpico7gJlbBVQg/132, createdBy=edaf2500125, createdName=ms3892185887221420, createdTime=Tue Mar 04 22:48:00 CST 2014, time=2014-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660092, encodeId=5f841660092ce, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Wed Mar 19 00:48:00 CST 2014, time=2014-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655322, encodeId=34cf165532261, content=<a href='/topic/show?id=7c2853311ac' target=_blank style='color:#2F92EE;'>#感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53311, encryptionId=7c2853311ac, topicName=感染性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=583d24724321, createdName=charl1234575, createdTime=Sun Jul 13 11:48:00 CST 2014, time=2014-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257581, encodeId=a2dc125e58192, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Sat Jan 04 05:48:00 CST 2014, time=2014-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618952, encodeId=bd17161895251, content=<a href='/topic/show?id=5f1785e9d5' target=_blank style='color:#2F92EE;'>#HCV感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8579, encryptionId=5f1785e9d5, topicName=HCV感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cb419968800, createdName=12498e5fm18(暂无昵称), createdTime=Sat Jan 04 05:48:00 CST 2014, time=2014-01-04, status=1, ipAttribution=)]
    2014-01-04 ymljack

    #HCV#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2077336, encodeId=b87820e7336eb, content=<a href='/topic/show?id=cb141845040' target=_blank style='color:#2F92EE;'>#Virol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18450, encryptionId=cb141845040, topicName=Virol)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdwx.qlogo.cn/mmopen/vi_32/FGFAawy0kQNXbuvUuLtUVrx5aKhOIkwqJwyxu0QlpLFIDSb1Ht19ptXvYBjuAoNBubibnNF3iazdpico7gJlbBVQg/132, createdBy=edaf2500125, createdName=ms3892185887221420, createdTime=Tue Mar 04 22:48:00 CST 2014, time=2014-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1660092, encodeId=5f841660092ce, content=<a href='/topic/show?id=8d0d28912db' target=_blank style='color:#2F92EE;'>#克隆#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=28912, encryptionId=8d0d28912db, topicName=克隆)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=596825099872, createdName=aids221, createdTime=Wed Mar 19 00:48:00 CST 2014, time=2014-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1655322, encodeId=34cf165532261, content=<a href='/topic/show?id=7c2853311ac' target=_blank style='color:#2F92EE;'>#感染性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53311, encryptionId=7c2853311ac, topicName=感染性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=583d24724321, createdName=charl1234575, createdTime=Sun Jul 13 11:48:00 CST 2014, time=2014-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257581, encodeId=a2dc125e58192, content=<a href='/topic/show?id=774e856e22' target=_blank style='color:#2F92EE;'>#HCV#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8567, encryptionId=774e856e22, topicName=HCV)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=460849, createdName=ymljack, createdTime=Sat Jan 04 05:48:00 CST 2014, time=2014-01-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1618952, encodeId=bd17161895251, content=<a href='/topic/show?id=5f1785e9d5' target=_blank style='color:#2F92EE;'>#HCV感染#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8579, encryptionId=5f1785e9d5, topicName=HCV感染)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9cb419968800, createdName=12498e5fm18(暂无昵称), createdTime=Sat Jan 04 05:48:00 CST 2014, time=2014-01-04, status=1, ipAttribution=)]
    2014-01-04 12498e5fm18(暂无昵称)

    #HCV感染#

    0

相关资讯

慢性丙型肝炎抗病毒药物的新进展

目前全球丙型肝炎病毒(HCV)感染率约为3％，我国的抗-HCV抗体阳性率约3．2％，尚无预防疫苗，以基因Ⅰ型为主(占80％)j其中又以Ⅰb型最为常见(占64％)。慢性丙型病毒性肝炎患者随着病情的发展进展为终末期肝硬化或肝癌，抗病毒治疗目标是清除或持续抑制体内的病毒，阻止病情进展恶化，提高患者的生活质量。临床上目前最常用的方案为聚乙二醇干扰素(PEG—IFNα)和利巴韦林联合。但是HCV基因Ⅰ型的持

中日对比：PEG IFN治疗慢性丙肝的疗效很大化

       【导语】目前，丙型肝炎病毒（HCV）感染率的不断升高，慢性丙型肝炎已成为继乙型病毒性肝炎后的又一重大病毒性肝病。据统计，全球抗-HCV血清阳性率为0.6%~3%。近年来抗HCV治疗取得了可喜进展。聚乙二醇干扰素（PEG IFN）/利巴韦林（RBV）标准方案的持续病毒学应答（SVR）率令人振奋，直接抗病毒药物（DAA）获准进入临床，有望形成新的治

Baidu
map
Baidu
map
Baidu
map